aromasil has been researched along with Disease Exacerbation in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Ciruelos, E; Conte, P; Gavila, J; Generali, D; Jerusalem, G; Lang, I; Martin, M; Martínez-Serrano, MJ; Montemurro, F; Neven, P; Perelló, MF; Tjan-Heijnen, VCG | 1 |
| Coudert, B; Goirand, F; Guérard, P; Macaire, P; Schmitt, A; Vaury, C | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Gourd, E | 1 |
| Adams, S; Bonakdar, M; Budan, B; Goldberg, JD; Gu, P; Iwano, A; Jhaveri, K; Kozhaya, L; Kwa, M; Li, X; Meyers, M; Muggia, F; Novik, Y; Oratz, R; Raad, R; Speyer, J; Tavukcuoglu, E; Unutmaz, D; Wu, J | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Baselga, J; Burris, HA; Campone, M; Eakle, J; El-Hashimy, M; Geberth, M; Gnant, M; Hadji, P; Hart, LL; Hortobagyi, GN; Iwata, H; Lebwohl, D; Mukai, H; Noguchi, S; Piccart, M; Pritchard, KI; Rao, S; Rugo, HS; Sahmoud, T; Taran, T | 1 |
| Baselga, J; Bauly, H; Beck, JT; Bennett, L; Burris, HA; Chouinard, E; Gnant, M; Hortobagyi, GN; Komorowski, A; Lebrun, F; Neven, P; Noguchi, S; Petrakova, K; Piccart, M; Pritchard, KI; Ricci, JF; Rugo, HS; Sahmoud, T; Taran, T; Young, R | 1 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Bachelot, T; Baselga, J; Beck, JT; Bennett, L; Burris, HA; Cahana, A; Campone, M; Gnant, M; Heng, DY; Horiguchi, J; Hortobagyi, GN; Komorowski, A; Neven, P; Noguchi, S; Nunzi, M; Piccart, M; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Taran, T; Zhang, J; Ziemiecki, R | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Láng, I; Rubovszky, G | 1 |
| Adunlin, G; Avancha, K; Diaby, V; Gluck, S; Lopes, G; Montero, AJ; Zeichner, SB | 1 |
| Bottini, A; Ciani, O; Generali, D; Jerusalem, G; Loi, S; Pusztai, L; Rognoni, C; Tarricone, R; Venturini, S | 1 |
| Ballatore, Z; Battelli, N; Berardi, R; Cascinu, S; De Lisa, M; Pagliacci, A; Pistelli, M | 1 |
| Arcusa, A; Barnadas, A; Gil, M; González, S; Margelí-Vila, M; Moreno, A; Muñoz, M; Prieto, L; Tusquets, I | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Glück, S; Untch, M; von Minckwitz, G | 1 |
| Ingle, JN | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L | 1 |
| Bowman, A; Cameron, D; Coleman, R; Dunn, K; Kunkler, I; Leonard, R; Manifold, I; Purohit, O; Steele, N; Zekri, J | 1 |
| Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F | 1 |
| Abbattista, A; Bapsy, P; Carpentieri, M; Dirix, LY; Falcon, S; Gomez, H; Ignacio, J; Jones, S; Lobelle, JP; Nag, S; Paridaens, R; Raghunadharao, D | 1 |
| Bonneterre, J; di Salle, E; Lanzalone, S; Murray, R; Paridaens, R; Piscitelli, G; Roché, H; Serin, D; Thürlimann, B; Zurlo, MG | 1 |
| Arkhipov, A; Bajetta, E; Cervek, J; di Salle, E; Dirix, LY; Dugardyn, JL; Fein, LE; Fowst, C; Jones, SE; Kaufmann, M; Massimini, G; Mennel, RG; Miller, LL; Nasurdi, C; Piscitelli, G; Polli, A; Zilembo, N | 1 |
| Beex, L; Biganzoli, L; Cufer, T; Dirix, L; Duchateau, L; Lobelle, JP; Lohrisch, C; Nooij, M; Paridaens, R; Piccart, M; Van Hoorebeeck, I | 1 |
| Lønning, PE | 1 |
4 review(s) available for aromasil and Disease Exacerbation
| Article | Year |
|---|---|
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Kaplan-Meier Estimate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Retreatment; Treatment Outcome | 2015 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease Management; Disease Progression; Drug Therapy, Combination; Female; Geriatric Assessment; Health Status; Humans; Letrozole; Life Expectancy; Nitriles; Prognosis; Quality of Life; Treatment Outcome; Triazoles | 2013 |
Exemestane in breast cancer: current status and future directions.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Survival Analysis | 2000 |
12 trial(s) available for aromasil and Disease Exacerbation
| Article | Year |
|---|---|
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Incidence; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Postmenopause; Progression-Free Survival; Receptors, Estrogen; Receptors, Progesterone; T-Lymphocytes, Regulatory | 2018 |
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Topics: Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Odds Ratio; Osteogenesis; Postmenopause; Procollagen; Proportional Hazards Models; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Drug Administration Schedule; Everolimus; Female; Health Status; Humans; Middle Aged; Odds Ratio; Postmenopause; Proportional Hazards Models; Quality of Life; Sirolimus; Surveys and Questionnaires; Treatment Outcome | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Health Status; Humans; Immunosuppressive Agents; Middle Aged; Placebos; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Surveys and Questionnaires; Treatment Outcome | 2013 |
Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Survival Analysis | 2009 |
Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Celecoxib; Disease Progression; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Pyrazoles; Sulfonamides; Tissue Distribution; Treatment Outcome | 2008 |
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Postmenopause; Treatment Outcome | 1997 |
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Pain; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.
Topics: Administration, Oral; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Tamoxifen; Treatment Outcome | 2000 |
12 other study(ies) available for aromasil and Disease Exacerbation
| Article | Year |
|---|---|
Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Piperazines; Pyridines | 2021 |
Switch to exemestane effective in early breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Substitution; Female; Humans; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
[BOLERO -- another remarkable step in treatment of breast cancer].
Topics: Adult; Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Markov Chains; Neoplasm Metastasis; Sirolimus | 2014 |
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms, Male; Cell Proliferation; Disease Progression; Disease-Free Survival; Estrogen Receptor alpha; Everolimus; Humans; Male; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome | 2016 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Female; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Random Allocation; Tamoxifen; Time Factors; Triazoles | 2004 |
Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Male; Receptors, Estrogen; Retrospective Studies; Treatment Failure | 2006 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Confidence Intervals; Disease Progression; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2005 |